Novartis announced a deal to acquire a Synnovation unit for $2 billion up front to secure SNV4818, a mutant‑selective PI3Kα inhibitor intended for HR+/HER2‑ breast cancer. The acquisition gives Novartis control of a next‑generation oral that aims to avoid on‑target toxicities seen with first‑generation PI3Kα inhibitors and enable broader combination strategies. Synnovation’s candidate is in early clinical testing with a primary study completion in 2027; Novartis framed the purchase as a defensive and strategic move to bolster its oncology franchise against competing mutant‑selective programs.